# A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

> **NCT04049266** · PHASE2,PHASE3 · TERMINATED · sponsor: **Kodiak Sciences Inc** · enrollment: 559 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** KSI-301
- **DRUG:** Aflibercept
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT04049266
- **Lead sponsor:** Kodiak Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-08
- **Primary completion:** 2021-11-17
- **Final completion:** 2022-04-26
- **Target enrollment:** 559 (ACTUAL)
- **Why stopped:** Primary Endpoint Not Met
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049266, "A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04049266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*